Sensus Healthcare, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022
January 05, 2023 at 04:05 pm
Share
Sensus Healthcare, Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2022. For the quarter, the company expected revenues To exceed $13 million. Fourth quarter 2022 revenues are expected to include more than $500,000 from the companyÆs aesthetics business.
For the full year 2022, revenues are expected to exceed $44 million, representing growth of approximately 60% over 2021. The company also expected that both the fourth quarter and the full year will be profitable.
Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The Company uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100+ offer remote diagnostics solutions, including operation tracking.
SENSUS HEALTHCARE, INC. 
